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novel avian-origin H7N9 influenza strain emerged in China in
April 2013. Since its re-emergence in
October–November 2013, the number
of reported cases has accelerated; more
than 220 laboratory-confirmed cases
and 112 deaths (case fatality rate of
20–30%) have been reported. The resurgence of H7N9 has re-emphasized the
importance of making faster and more
effective influenza vaccines than those
that are currently available. Recombinant H7 hemagglutinin (H7-HA) vaccines have been produced, addressing
the first problem. Unfortunately, these
recombinant subunit vaccine products
appear to have failed to address the second problem, influenza vaccine efficacy.
Reported unadjuvanted H7N9 vaccine
seroconversion rates were between 6%
and 16%, nearly 10-fold lower than rates
for unadjuvanted vaccine seroconversion
to standard H1N1 monovalent (recombinant) vaccine (89% to pandemic H1N1).
Could this state of affairs have been predicted? As it turns out, yes, and it was.1
In that previous analysis of available
H7-HA sequences, we found fewer T-cell
epitopes per protein than expected, and
predicted that H7-HA-based vaccines
would be much less antigenic than recent
seasonal vaccines. Novel approaches to
developing a more immunogenic HA
were offered for consideration at the
time, and now, as the low immunogenicity of H7N9 vaccines appears to indicate,
they appear to be even more relevant.

More effective H7N9 influenza vaccines
can be produced, provided that the role
of T-cell epitopes is carefully considered,
and accumulated knowledge about the
importance of cross-conserved epitopes
between viral subtypes is applied to the
design of those vaccines.

Introduction
A new avian-origin influenza, known
initially as H7N9 A/Anhui/1/2013
(H7N9), emerged near Shanghai beginning in February, peaking in May–June
and losing momentum in July 2013.2
After a period of quiescence, case reports
accelerated in October 2013: more than
220 cases of H7N9 have occurred as of
February 2014.3 The high mortality rate
(case fatality rate or CFR of 20–30%) and
rapid spread of the new strain of H7N9
throughout China4 is renewing concern
about the availability of effective antiH7N9 vaccines. A number of H7N9 vaccines are in clinical trials; however, the
efficacy of these vaccines is reported to
be extremely low compared with other
subunit and seasonal influenza vaccines,
as shown in Figure 1. While the addition
of adjuvant to the vaccines did increase
the antigenicity of the vaccines in young,
healthy adults, adjuvant is not currently
used in standard seasonal influenza vaccines. Experts have expressed some concern about the use of adjuvant in influenza
vaccination due to the recently reported
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Now even more relevant to (H7N9) influenza vaccine design

association between adjuvanted influenza
vaccines and narcolepsy in Finnish (and
Swedish) children.5
The H7N9 genome was first made
available on the GISAID website on April
2, 2013; it was rapidly analyzed and compared with other circulating H7-type
viruses6-8 and examined for potential
antigenicity by our group.1 By early 2013,
European, American, and Asian influenza
vaccine companies were entering clinical trials with recombinant subunit vaccines produced in protein-production cell
lines.9,10
Our group viewed this approach to the
production of H7N9 vaccines with some
concern, because our previous analysis
of the H7-HA sequence indicated that
it had fewer than expected T-cell epitopes and would be poorly antigenic.1
This analysis appears to be even more
relevant in light of the new H7N9 vaccine efficacy data. Briefly, we estimated
the immunogenic potential of the new
influenza using well-established immunoinformatics tools.11-13 We then normalized the H7-HA T-cell epitope content to
protein length, and compared it to other
circulating influenza strains. As shown in
Figure 2, H7-HA proteins and HA tested
in H7N7 and H7N1 vaccines were found
to contain 14–24% fewer T-cell epitopes (per length) than other circulating
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strains of IAV (A/California/07/2009,
A/Victoria/361/2011,
and
A/
Texas/50/2012).
H7-HA also appeared to be “deimmunized” and “tolerized” with respect
the quantity and quality of T-cell epitopes expected in proteins of similar size
(Fig. 2). De-immunization, or removal
of T-cell epitopes, is a method employed
by some viruses to evade human immune
response. Tolerization relates to the introduction of T-cell epitopes that are highly
conserved, on the T-cell receptor face,
with a large number of other similar epitopes contained in the human genome.
We recently observed de-immunization
and tolerization of T-cell epitopes to be
prevalent among viruses that are known to
be commensal in human beings, such as
Herpes simplex virus, Cytomegalovirus,
and Epstein Barr virus.14 This type of
epitope analysis is especially relevant
to influenza vaccine design, since the
principles of protein engineering could
be applied to correct these features and
improve the antigenicity of recombinant subunit HA-based vaccines. Using
a similar approach, we correctly predicted the antigenicity of influenza A/
California/04/2009 (H1N1), which is due
in part to its substantial ration of T helper
epitopes with the potential to cross-react
with other seasonal H1N1 strains,15,16 a
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H7N9 Vaccines: Current Status
Two vaccine studies20,21 and one clinical serology study of H7N9-infected and
exposed subjects22 have been published
or announced in the last few months.
Novartis produced a monovalent inactivated vaccine in MDCK cells,9 and
Novavax produced a virus-like particle
vaccine in insect cells.10 The reported seroconversion rates to unadjuvanted H7N9
HA vaccines were extremely low (6–16%)
as compared with the 89% seroconversion rate observed in response to subunit
influenza vaccines in comparable studies
of pandemic H1N1 HA.23-25 According
to the Novartis media release, the vaccine’s protective immune response was
only achieved after two doses of 15 µg of
the MF59-adjuvanted vaccine (protective
HAI titers in 85% of healthy subjects, 400
healthy volunteers, 18–64 y of age). In
contrast, “…only 6% of subjects achieved
a protective response when given two
doses of the 15 µg unadjuvanted vaccine.”
Similarly low hemagglutination-inhibition (HAI) titers were achieved in the
Novavax study: seroconversion and reciprocal antibody titers of 40 or more (…the
value cited by regulatory authorities as
having a potential association with clinical
benefit) were only detected in 5.7% and
15.6% of participants receiving 15 μg and
45 μg of HA, respectively, without adjuvant. Addition of adjuvant to the Novavax
vaccine significantly increased the level
of HAI titers; more than 80% of participants receiving 5 μg of the HA vaccine
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Figure 1. Comparative effectiveness of unadjuvanted monovalent recombinant vaccines (IAV
H7N9 and H1N1) and seasonal trivalent vaccine. Percent effectiveness is shown, as percent of study
cohort achieving “significant” seroconversion (see text). The Novartis vaccine company reported
that H7N9 cell culture-produced vaccine without adjuvant produced seroconversion rates of 6%. 20
In contrast, the rate of seroconversion to unadjuvanted monovalent pandemic H1N1 was 89% in
one study.23 Rates of seroconversion to trivalent seasonal vaccine are 84% on average to the three
strains of virus in the vaccine.25

finding that was later validated in studies
performed by other groups.17-19
H7-HA stands out as a uniquely nonimmunogenic protein, which may be due
to the paucity of T-cell epitopes that we
described previously and to cross-conserved epitopes (with the human genome)
that may further reduce its antigenicity.
Here, we reiterate our hypothesis that
the emerging avian-origin H7N9 2013
might behave like a “stealth” virus, using
the T-cell epitope deimmunization and
tolerization methods to evade human
cellular and humoral immune response,
and review these findings in the context
of recently published vaccine efficacy and
human serology reports.

Human Infection
and Seroconversion
In the recent noteworthy seroepidemiology study performed by Guo et al.,
the protective antibody response against
influenza A (H7N9) virus was investigated in 48 acute-phase and convalescent serum samples from 21 subjects
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Figure 2. EpiMatrix Immunogenicity scale comparing the potential antigenicity of H7-HA to recent
seasonal influenza A strain HA proteins. Using EpiMatrix and assessing each protein for overall
T-cell epitope content, the protein scores are plotted on an immunogenicity scale that ranks the
immunogenic potential of HA protein derived from recently-circulating strains of seasonal IAV
(H1N1, H3N2) as compared with strains of avian-origin influenza. The set of avian-origin IAV strains
have a low immunogenicity potential (below zero), EpiMatrix scores that are commonly associated with low immunogenicity proteins that do not effectively trigger IgG antibody responses.
Scores are shown for H7-HA from several different sources, including the vaccines described in
the text (refs. 22 and 23 [Anhui, scoring – 6.49], 28 [mallard, –7.12], and 29 [chicken, –6.43]). In contrast, H1N1 California, H3N2 Victoria, and H2N3 Texas, rank +19.22, +16.23, and +14.25 respectively).
The EpiMatrix Immunogenicity Scale is derived by analyzing more than 10 000 random protein
sequences for T cell epitope content and producing a score that reflects the normal distribution of
T cell epitope content per protein length. Proteins scoring higher than 10 on this scale are usually
antigenic; proteins scoring lower than 10 are generally poorly antigenic. Details on the methodology are available in reference 13 and other publications by the group.

with laboratory-confirmed infection.24
Neutralizing anti-H7-HA antibodies
were undetectable in samples collected
up to 28 d after symptom onset but were
observed at 29–37 d. This differs significantly from responses in pandemic H1N1
and H5N1 infections, which are observed
at days 14–21. The avidity of serum IgG
antibodies for H7-HA was also lower than
that observed for H1-HA and H3-HA.
Thus, the H7N9 virus infection stimulated
delayed and weak antibody responses in
the cases investigated by Guo et al., suggesting that vaccination using conventional
approaches may also be inefficient.
According to the authors, weak antibody response and low avidity of the resulting anti-HA antibodies might play a role in
the severity and duration of infections and
the pathogenesis of H7N9 disease. The low
titer of antibodies to HA resulting from
infection is also noteworthy since serology
is also used to detect infection in large population studies. If antibody titers are low
among infected individuals, it is possible
that the prevalence of exposure to H7N9
might be underreported. One consequence
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of under-diagnosis is known as the tip of
the iceberg phenomenon (prevalence is
underestimated due to under-reporting).
Indeed, a number of H7N9 cases in China
were only identified following routine serosurveillance.30 Should human-to-human
transmission of H7N9 begin, other means
of identifying infected individuals in large
surveys (such as T-cell assays) may be
needed, as they may prove to be more accurate than serology.

Epidemiology, Morbidity,
and Mortality
The first cases of human infection with H7N9 were detected in residents of the city of Shanghai and in
residents of Anhui province.2 The number of cases peaked in May–June and
decreased during the summer, but the
virus re-emerged in October 2013.6 As of
February 1st 2014, more than 280 laboratory-confirmed cases of human infection have already been reported. That
is nearly half as many as have occurred
for H5N1 (566, as of December 2014),
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with 60 units of adjuvant saponin-based
ISCOMATRIX adjuvant seroconverted.
The low immunogenicity of H7-HA
has been previously reported in pre-clinical (mouse) and clinical (human) studies.
In one such previous study, a low-pathogenicity recombinant H7N7 virus was
generated by reverse genetics and shown
to protect mice against lethal infection
with a high-pathogenicity H7N7 virus.
Importantly, protection was only achieved
with co-administration of adjuvant.26 This
subunit vaccine was developed by cloning
the HA of influenza virus A/Mallard/
Netherlands/12/00 (H7N3) and the NA
of influenza virus A/Netherlands/33/03
(H7N7) into the cell culture-adapted
strain A/PR/8/34.
In a second study, a split H7N1 vaccine was prepared by reverse genetics and
produced in a specialized cell line (PER.
C6). The vaccine contained the internal
genes of A/PR/8/34 with surface antigens
of the highly pathogenic avian strain (A/
Chicken/Italy/13474/l99(H7N1). This
vaccine was also observed to be poorly
immunogenic in a Phase I clinical trial27
even when given in two doses containing
either 12 μg or 24 μg of HA alone or with
aluminum hydroxide (Alum) adjuvant.
This vaccine was found to induce only low
antibody responses in humans, and again,
only when formulated with the adjuvant.
These findings may have contributed
to the decision by vaccine developers to
compare unadjuvanted and adjuvanted
H7N9 vaccines in side-by-side cohorts in
the recent clinical studies described above.
Adjuvanting H7N9 influenza vaccines is
one approach to improving the antigenicity of H7-HA, and it may become necessary, but emerging associations between
adjuvanted influenza vaccination and narcolepsy in Finland and Sweden5,28,29 raise
concern about the potential for adverse
immune responses to occur.

and they are accumulating at a pace that
is five times faster than H5N1. Even
more worrisome, the number of cases
reported in a single province (Zhejiang)
over the last two-month period
(December 2013–January 2014) already
exceeds the peak number of cases in the
same region, per two month period, last
year.31
H7N9 is “non-pathogenic” in birds
but pathogenic in humans. In humans,
the CFR is 22%3 ; some experts believe
that there are quite a few cases that are not
laboratory-confirmed, thus the CFR may
be lower. Most patients initially developed
an influenza-like illness that progressed to
respiratory distress syndrome.2 The median
age of laboratory-confirmed cases is 56 y,
but there is a wide age range (from infant to
91). Infections in men are more frequently
reported than in women. In a recent study
of 82 confirmed cases with information on
possible exposures, 63 (77%) of the cases
had contact with live animals at or near
the time of infection.4,5 Poultry and other
live birds (including pet birds) have been
identified as the likely source of infection,
although the prevalence of H7N9 influenza
in poultry flocks remains extremely low,
and a direct link has not yet been proven.
The lack of any evidence of circulating
H7N9 in poultry has lead some to postulate that another, potentially mammalian,
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vector is transmitting H7N9 to humans.
Of note, the virus appears to have a “mammalian signature,” according to experts
at the National Institute for Infectious
Disease.9

Public Health Concerns
There are four important reasons why
public health officials are on high alert
regarding H7N9: First, individual cases of
nearly identical H7N9 viral infections have
been identified in a wide range of locations within China in a very short period
of time. Cases have been reported from 11
provinces in China and two municipalities
(Beijing and Shanghai). Taiwan reported
two cases imported from Jiangsu, and
Hong Kong reported three cases imported
from Guangdong.4 The wide distribution
of cases strongly suggests that the virus is
already widespread in an as-yet-unidentified reservoir population, although humanto-human transmission is rare.32 Second,
H7N9 subtype influenza has never before
infected humans to a significant extent,
meaning the human population has little
or no pre-existing immunity. This clearly
contributes to the extremely high mortality rate, which ranges between 20 and 30%
of individuals.33,34 Third, higher rates of
human infection by the emerging H7N9,
as reported to occur over the most recent
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Figure 3. Contrasting TCR-epitope networks of ‘classic’ T-cell epitopes from pH1N1 and H7N9
HA. Human genome T cell epitope conservation defined by JanusMatrix53 is illustrated using
Cytoscape. Here, the more limited human conservation of TCR-facing residues for the T cell epitope
in Influenza A/H1N1 2009/CA (pH1N1; three 9-mers, with 0, 2, or 8 human conserved epitopes),
contrasts with a similar epitope in H7N9 (three 9-mers, with 9, 13, or 2 human conserved epitopes).
A detailed description of the JanusMatrix tool is available in reference 53.

time period, are worrisome because each
transmission may be associated with mutations in the viral sequence that increase the
likelihood of human-to-human transmission. The pace of human infection appears
to have accelerated in recent months.3
According to a recently-published report,
the virus can be transmitted between
mammals (guinea pigs and ferrets).35,36
More infections may lead to the chance
occurrence of the one or two mutations
that would enable either drug resistance to
occur,37 or enable the virus to achieve full
adaptation for human-to-human transmission.30 And fourth, there is no reason to
believe that the H7N9 virus will remain
geographically confined to China. Not
only do wild bird flyways provide a convenient route of spread to Africa, Europe, and
North America,38,39 but also human flyways40 (see the recent report of the arrival of
H5N1 in North America, ref. 41) provide
an easy means to transmit H7N9, should
mutations to H7N9 that enable human-tohuman transmission occur.
Transport of H7N9 along poultry trade
routes or wild bird migration routes appears
to be highly likely (Fig. 3). Should H7N9
spill over the borders of China to nearby
countries such as Vietnam (through local,
unregulated poultry trade), or more distantly by bird flyways to Africa, it is likely
to cause an even greater number of human
cases. Poultry stock is ubiquitous and contact between humans and food animals
is extensive in most developing world
countries. In addition, influenza vaccination campaigns are unheard of, although
infrastructure does exist for door-to-door
vaccination programs; these have been
implemented in the context of polio outbreaks. Little is known about the epidemic
burden of IAV among African communities, and information about IAV circulation in the population has only emerged
recently (with H1N1 in 2009).42 From
those studies, it is clear that IAV can be
introduced by two routes: first by travelers, (e.g., Malian workers returning home
from Europe42); and second by birds. One
important location where avian transmission might occur is the inner Niger Delta
in Mali, a wetland of 3 000 000 hectares
with flood plains, lakes, river branches,
and small pockets of flood forest that
plays an extremely important role in bird

Novel Vaccines: Strategies That
Will Work
Should H7N9 develop pandemic
potential, novel strategies for improving the immunogenicity of vaccines for
this unique low-immunogenicity strain
of avian-origin influenza will be needed.
Several approaches to improving the next
generation of H7N9 or other IAV vaccines
are reviewed here.
Introduction of cross-conserved T-cell
epitopes
In 2009, we anticipated the importance of cross-conserved epitopes in the
context of pandemic H1N1 influenza in
a comprehensive analysis that was published shortly after the emergence of
the new strain.15 There was considerable
support for this hypothesis in published
studies involving exposure or vaccination and heterotypic challenge in animal
models.21,45-47 Thus, we argued, the reason
for the unusual age distribution of H1N1
2009 cases was that older individuals
might have established a cross-reactive
cell-mediated immune response to novel
H1N1 due to vaccination or exposure to
previously-circulating influenza H1N1
(from strains circulating after the 1918
epidemic and again in 197748 ). While
cross-reactive memory T-cell responses
(in the absence of a cross-reactive
humoral immune response) may not have
provided complete protection against
infection, it is possible that the severity of
the illness was reduced, leading to a lower
hospitalization rate and lower reports of
H1N1 in this age group, as was observed
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Figure 4. Wild bird flyways showing the connection between Asia and Africa. From Ian Mackay’s
blog “Viruses Down Under,” bird flyways that may contribute to H7N9 spread. Used with permission from http://virologydownunder.blogspot.com/2013/09/h7n9-in-wild-birdsa-review-of-literature.html, accessed 1 February 2014.

in a case-control study from Mexico.49
Since then, we have carried this work further by confirming the predictions and
developing novel vaccines that incorporate highly cross-strain-conserved CD4+
T-cell epitopes across a broad range of
H1N1 influenza sequences.50-52 Similarly,
H7N9 epitopes that are conserved in circulating seasonal influenza strains may
contribute to recovery from infection.
Serum IgG samples from H7N9-infected
patients were shown to recognize H1 and
H3 hemagglutinins,24 suggesting that a
portion of their influenza memory CD4+
T-cell repertoire may cross-react with
H7N9 sequences. Thus, introduction of
T-cell epitopes that are highly cross-conserved (with other seasonal influenza A
strains), or attaching an epitope string to
HA, might boost the humoral immune
response to H7-HA. We are currently
engaged in the production of an epitopeboosted H7 protein.
Reduction of T-cell epitopes that
might lower immunogenicity
Before moving forward with vaccines
containing highly cross-conserved T-cell
epitopes, we have become interested in
determining whether epitopes conserved
with the human genome might also
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influence the immunogenicity of H7N9
HA. We recently published a description of the differential distribution of
epitopes that are highly cross-conserved
with the human genome among human
viral pathogens. Not surprisingly, commensal viruses such as Herpes simplex
virus 1 and 2, Epstein Barr virus, and
Cytomegalovirus had more of these types
of epitopes that are cross-conserved with
the human genome, than human pathogens that are not commensal (Variola and
Marburg viruses, for example14). Access to
advanced computational TCR-modeling
technology such as the JanusMatrix tool53
make it possible to screen for such potential cross-reactivities. In research that is
in preparation for publication, we have
identified human genome-conserved
epitopes derived from H7N9 influenza
that may diminish T-cell responsiveness
and significantly influence the outcome
of vaccination and infection. Shown in
Figure 4 are similar HA protein epitopes derived from H1N1 and H7N9. In
preliminary studies using PBMCs from
H7N9-naïve donors, we found that (1)
H7N9-unique epitopes generated limited immune responses in human IFNγ
ELISpot assays; (2) H7N9 epitopes that
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migration throughout Africa. Endogenous
circulation of H1N1 has been observed on
the Inner Niger Delta, where the human
seroconversion rate has been reported to be
about 13%.43 A third factor that may also
contribute to the spread of H7N9 to developing world countries, should human-tohuman transmission become possible, is
the increased mobility of Chinese workers
worldwide.44 Taken together, the potential
for H7N9 is of great concern for developing world countries in Asia and Africa.
Scientists, infectious disease experts, and
public health officials are watching the reemergence of H7N9 and its spread within
China with growing concern.

Conclusion
H7N9 viruses, along with many other
emerging subtypes influenza, challenge
our thinking on how to develop faster,
more efficacious vaccines. Seasonal influenza viruses have adapted to the human
host for many years following the introduction of a novel subtype. Therefore,
humans have memory immune responses
that can be recalled in a traditional influenza vaccine each flu season. In contrast,
people have no memory responses to new,
emerging influenza. Following the emergence of novel H1N1, we determined that
many cross-reactive T-cell epitopes were
present in the viral genome, and a crossreactive T-cell response was subsequently
shown to contribute to significant protection against the novel strain. In contrast,
as the analysis of critical H7N9 gene
products (HA, NA) demonstrates, there
is only limited potential for cross-reactive
immune responses to this novel, avianorigin influenza strain.
The challenge of developing an efficacious H7N9 vaccine is further heightened
by the presence of T-cell epitopes in the
H7N9 HA that may cross-react with the
human genome, which may alter or suppress immune response to the emerging
H7N9 virus. This landscape forces vaccinologists and vaccine manufacturers to
think outside the box and develop novel
strategies to enhance the immunogenic
potential for vaccines against these viruses.
Careful vaccine engineering that enriches
for immunogenic T-cell epitopes appears
to be an excellent strategy to enhance
both the antibody and cellular responses
against H7N9 antigens, thereby reducing
viral titers in the nasal and lung mucosa,
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reducing transmission, and protecting
against severe morbidity and death.

6.

7.

Disclosure of Potential Conflicts of Interest

Coauthors A.D.G., W.M., L.M., and
F.T. are employees of EpiVax, and two
(A.D.G., W.M.) are majority stockholders.
These authors recognize the presence of a
potential conflict of interest and affirm
that the information represented in this
paper is original and unbiased observations. R.L., A.H.G., O.A.K., and T.M.R.
declare no competing interests.

8.

9.

Acknowledgments

The authors each made substantial
contributions to conception and design,
acquisition of data or analysis, and interpretation of data; they also contributed
to drafting the article or reviewing/revising it critically for important intellectual
content. They are grateful to AJ Vincelli,
Christine Boyle, and Kelsey Confreda of
EpiVax for their many contributions to
the finalization of this manuscript, and to
Matt Ardito for the initial immunoinformatics analysis.
References
1.

2.

3.

4.

5.

De Groot AS, Ardito M, Terry F, Levitz L, Ross T,
Moise L, Martin W. Low immunogenicity predicted
for emerging avian-origin H7N9: implication for
influenza vaccine design. Hum Vaccin Immunother
2013; 9:950-6; PMID:23807079; http://dx.doi.
org/10.4161/hv.24939
Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen
J, Jie Z, Qiu H, Xu K, et al. Human infection with a
novel avian-origin influenza A (H7N9) virus. N Engl
J Med 2013; 368:1888-97; PMID:23577628; http://
dx.doi.org/10.1056/NEJMoa1304459
As 8 new H7N9 influenza infections confirmed in
Jiangsu Province, Zhejiang Province and Guangdong
Province in China, CECC for H7N9 influenza
advises people traveling overseas to take preventive
measures to ward off infection [Internet]. Taipei
City, Taiwan (R.O.C.): CDC. (Centers for Disease
Control), R.O.C. (Taiwan); 2014 29 Jan [cited 2014
29 Jan]. Available from: http://www.cdc.gov.tw/english/info.aspx?treeid=bc2d4e89b154059b&nowtreei
d=ee0a2987cfba3222&tid=03ECBB84CD82E4FB.
Rapid risk assessment: Human infection with a novel
avian influenza A(H7N9) virus, China – Third
update [Internet]. Stockholm, Sweden: European
Centre for Disease Prevention and Control; 2014
27 Jan [cited 2014 27 Jan]. Available from: http://
ecdc.europa.eu/en/publications/Publications/influenza-AH7N9-China-rapid-risk-assessment-27-January-2014.pdf
Partinen M, Saarenpää-Heikkilä O, Ilveskoski I,
Hublin C, Linna M, Olsén P, Nokelainen P, Alén
R, Wallden T, Espo M, et al. Increased incidence
and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination
campaign in Finland. PLoS One 2012; 7:e33723;
PMID:22470463; http://dx.doi.org/10.1371/journal.pone.0033723

Human Vaccines & Immunotherapeutics

10.

12.

13.

14.

15.

16.

17.

GISAID: Global Initiative on Sharing all Influenza
Data [Internet]. Munich: GISAID; [cited date: 1 Feb
2014]. Available from: http://platform.gisaid.org
Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, Bi Y, Wu
Y, Li X, Yan J, et al. Origin and diversity of novel avian
influenza A H7N9 viruses causing human infection:
phylogenetic, structural, and coalescent analyses.
Lancet 2013; 381:1926-32; PMID:23643111; http://
dx.doi.org/10.1016/S0140-6736(13)60938-1
Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada
S, Uchida Y, Neumann G, Saito T, Kawaoka Y,
Tashiro M. Genetic analysis of novel avian A(H7N9)
influenza viruses isolated from patients in China,
February to April 2013. Euro Surveill 2013;
18:20453; PMID:23594575
Dormitzer PR, Suphaphiphat P, Gibson DG,
Wentworth DE, Stockwell TB, Algire MA,
Alperovich N, Barro M, Brown DM, Craig S, et al.
Synthetic generation of influenza vaccine viruses
for rapid response to pandemics. Sci Transl Med
2013; 5:85ra68; PMID:23677594; http://dx.doi.
org/10.1126/scitranslmed.3006368
Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z,
Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn
GM. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013
(H7N9) protection and heterologous A/chicken/
Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine
2013; 31:4305-13; PMID:23891795; http://dx.doi.
org/10.1016/j.vaccine.2013.07.043
11. De Groot AS, Ardito MA, Tassone R, Knopf
P, Moise L, Martin W. Development of Vaccines:
From Discovery to Clinical Testing. First Edition.
John Wiley and Sons; c2011. Chapter 3, Tools for
Vaccine Design: Prediction and Validation of Highly
Immunogenic and Conserved Class II Epitopes
and Development of Epitope-driven Vaccines.
pp. 65-94. Available from: http://tinyurl.com/
Dvt-of-Vaccines-Chapt-3
Moise L, McMurry JA, Buus S, Frey S, Martin WD,
De Groot AS. In silico-accelerated identification of
conserved and immunogenic variola/vaccinia T-cell
epitopes. Vaccine 2009; 27:6471-9; PMID:19559119;
http://dx.doi.org/10.1016/j.vaccine.2009.06.018
Moise L, Buller RM, Schriewer J, Lee J, Frey SE,
Weiner DB, Martin W, De Groot AS. VennVax, a
DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against
vaccinia infection by T-cell response alone. Vaccine
2011; 29:501-11; PMID:21055490; http://dx.doi.
org/10.1016/j.vaccine.2010.10.064
He L, De Groot AS, Gutierrez AH, Martin WD,
Moise L, Bailey-Kellogg C. Integrated assessment
of predicted MHC binding and cross-conservation
with self reveals patterns of viral camouflage. BMC
Bioinformatics 2014; (Forthcoming)
De Groot AS, Ardito M, McClaine EM, Moise
L, Martin WD. Immunoinformatic comparison
of T-cell epitopes contained in novel swine-origin
influenza A (H1N1) virus with epitopes in 20082009 conventional influenza vaccine. Vaccine
2009; 27:5740-7; PMID:19660593; http://dx.doi.
org/10.1016/j.vaccine.2009.07.040
De Groot AS, McClaine E, Moise L, Martin W. Time
for T?: Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T-cell epitopes in the
next generation of influenza vaccines. Hum Vaccin
2010; 6:161-3; PMID:20431339; http://dx.doi.
org/10.4161/hv.6.2.11333
Greenbaum JA, Kotturi MF, Kim Y, Oseroff C,
Vaughan K, Salimi N, Vita R, Ponomarenko J,
Scheuermann RH, Sette A, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in
the general human population. Proc Natl Acad Sci U
S A 2009; 106:20365-70; PMID:19918065; http://
dx.doi.org/10.1073/pnas.0911580106

261

©2014 Landes Bioscience. Do not distribute.

were highly cross-conserved with other
circulating strains generated strong T-cell
responses, and (3) epitopes that are crossconserved with the human genome and
with other circulating strains generated
diminished T-cell responses, by comparison (Rui Liu, unpublished). What is not
yet known, and will be critical to define,
is how these opposing T-cell responses
are integrated in an individual’s protective immune response, as measured by
the generation of effective neutralizing
(HAI) and binding antibodies.

262

30. Ip DK, Liao Q, Wu P, Gao Z, Cao B, Feng L, Xu X,
Jiang H, Li M, Bao J, et al. Detection of mild to moderate influenza A/H7N9 infection by China’s national
sentinel surveillance system for influenza-like illness:
case series. BMJ 2013; 346:f3693; PMID:23798720;
http://dx.doi.org/10.1136/bmj.f3693
31. Mackay IM. H7N9: Zhejiang in 50 cases... Virology
Down Under blog; 2014 30 Jan [cited 2014 31 Jan].
Available from: http://virologydownunder.blogspot.
com.au/
32. Number of confirmed human cases for avian influenza A(H7N9) reported to WHO: Report 3 – data
in WHO/HQ as of 24 April 2013, 14:45 GMT+1
[Internet]. Geneva, Switzerland; World Health
Organization; 2013 Apr 24 [cited 2014 Jan 29].
Available from from: http://www.who.int/influenza/
human_ anima l _interface /inf luenza _ h7n9 / 03_
ReportWebH7N9Number.pdf
33. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang
N, Chen E, Tang F, Wang D, et al. Epidemiology
of human infections with avian influenza A(H7N9)
virus in China. N Engl J Med 2014; 370:52032; PMID:23614499; http://dx.doi.org/10.1056/
NEJMoa1304617
34. Dudley JP, Mackay IM. Age-specific and sexspecific morbidity and mortality from avian influenza A(H7N9). J Clin Virol 2013; 58:568-70;
PMID:24091087;
http://dx.doi.org/10.1016/j.
jcv.2013.09.004
35. Gabbard JD, Dlugolenski D, Van Riel D, Marshall
N, Galloway SE, Howerth EW, Campbell PJ, Jones
C, Johnson S, Byrd-Leotis L, et al.; JD. Novel H7N9
Influenza Virus Shows Low Infectious Dose, High
Growth Rate, and Efficient Contact Transmission
in the Guinea Pig Model. J Virol 2014; 88:150212; PMID:24227867; http://dx.doi.org/10.1128/
JVI.02959-13
36. Richard M, Schrauwen EJ, de Graaf M, Bestebroer
TM, Spronken MI, van Boheemen S, de Meulder
D, Lexmond P, Linster M, Herfst S, et al. Limited
airborne transmission of H7N9 influenza A
virus between ferrets. Nature 2013; 501:5603; PMID:23925116; http://dx.doi.org/10.1038/
nature12476
37. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada
S, Uchida Y, Neumann G, Saito T, Kawaoka Y,
Tashiro M. Genetic analysis of novel avian A(H7N9)
influenza viruses isolated from patients in China,
February to April 2013. Euro Surveill 2013;
18:20453; PMID:23594575
38. Pérez-Ramírez E, Gerrikagoitia X, Barral M, Höfle
U. Detection of low pathogenic avian influenza
viruses in wild birds in Castilla-La Mancha (south
central Spain). Vet Microbiol 2010; 146:200-8;
PMID:20605691;
http://dx.doi.org/10.1016/j.
vetmic.2010.05.008
39. Bahl J, Krauss S, Kühnert D, Fourment M, Raven G,
Pryor SP, Niles LJ, Danner A, Walker D, Mendenhall
IH, et al. Influenza a virus migration and persistence in North American wild birds. PLoS Pathog
2013; 9:e1003570; PMID:24009503; http://dx.doi.
org/10.1371/journal.ppat.1003570
40. Colizza V, Barrat A, Barthelemy M, Valleron AJ,
Vespignani A. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med 2007; 4:e13; PMID:17253899;
http://dx.doi.org/10.1371/journal.pmed.0040013
41. First Human Avian Influenza A. (H5N1) Virus
Infection Reported in Americas [Internet]. Atlanta,
Georgia: Centers for Disease Control and Prevention;
2014 Jan 8 [cited 2014 Jan 29]. Available from:
http://cdc.gov/flu/news/first-human-h5n1-americas.
htm
42. Pandemic (H1N1) 2009 in the African region: update
66 [Internet]. Geneva, Switzerland: World Health
Organization; 2009 [cited 01 Feb 2014]. Available
from: http://www.who.int/csr/don/2009_09_18/en/

Human Vaccines & Immunotherapeutics

43. Koita OA, Sangare L, Poudiougou B, Aboubacar
B, Samake Y, Coulibaly T, Pronyk P, Salez N,
Kieffer A, Ninove L, et al. A seroepidemiological study of pandemic A/H1N1(2009) influenza in
a rural population of Mali. Clin Microbiol Infect
2012; 18:976-81; PMID:22221838; http://dx.doi.
org/10.1111/j.1469-0691.2011.03725.x
44. Kuang EMM. The new Chinese migration flows to
Africa. Soc Sci Inf (Paris) 2008; 47:643-59; http://
dx.doi.org/10.1177/0539018408096452
45. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G,
Katz JM, Pushko P, Tumpey TM. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1
influenza virus challenge. J Virol 2009; 83:572634; PMID:19321609; http://dx.doi.org/10.1128/
JVI.00207-09
46. Bright RA, Carter DM, Crevar CJ, Toapanta FR,
Steckbeck JD, Cole KS, Kumar NM, Pushko P,
Smith G, Tumpey TM, et al. Cross-clade protective
immune responses to influenza viruses with H5N1
HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3:e1501; PMID:18231588;
http://dx.doi.org/10.1371/journal.pone.0001501
47. Laurie KL, Carolan LA, Middleton D, Lowther S,
Kelso A, Barr IG. Multiple infections with seasonal
influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus
in a ferret model. J Infect Dis 2010; 202:1011-20;
PMID:20715930; http://dx.doi.org/10.1086/656188
48. Hodder RA, Gaydos JC, Allen RG, Top FH Jr.,
Nowosiwsky T, Russell PK. Swine influenza A at Fort
Dix, New Jersey (January-February 1976). III. Extent
of spread and duration of the outbreak. J Infect Dis
1977; 136(Suppl):S369-75; PMID:606761; http://
dx.doi.org/10.1093/infdis/136.Supplement_3.S369
49. Garcia-Garcia L, Valdespino-Gómez JL, LazcanoPonce E, Jimenez-Corona A, Higuera-Iglesias A,
Cruz-Hervert P, Cano-Arellano B, Garcia-Anaya A,
Ferreira-Guerrero E, Baez-Saldaña R, et al. Partial
protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1
2009: case-control study in Mexico City. BMJ
2009; 339:b3928; PMID:19808768; http://dx.doi.
org/10.1136/bmj.b3928
50. Schanen BC, De Groot AS, Moise L, Ardito M,
McClaine E, Martin W, Wittman V, Warren WL,
Drake DR 3rd. Coupling sensitive in vitro and in
silico techniques to assess cross-reactive CD4(+) T
cells against the swine-origin H1N1 influenza virus.
Vaccine 2011; 29:3299-309; PMID:21349362;
http://dx.doi.org/10.1016/j.vaccine.2011.02.019
51. Moise L, Terry F, Ardito M, Tassone R, Latimer H,
Boyle C, Martin WD, De Groot AS. Universal H1N1
influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980
and 2011. Hum Vaccin Immunother 2013; 9:1598607; PMID:23846304; http://dx.doi.org/10.4161/
hv.25598
52. Moise L, Tassone R, Latimer H, Terry F, Levitz L,
Haran JP, Ross TM, Boyle CM, Martin WD, De
Groot AS. Immunization with cross-conserved
H1N1 influenza CD4+ T-cell epitopes lowers viral
burden in HLA DR3 transgenic mice. Hum Vaccin
Immunother 2013; 9:2060-8; PMID:24045788;
http://dx.doi.org/10.4161/hv.26511
53. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F,
Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein
MB, Losikoff PT, Martin WD, et al. The two-faced
T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother
2013; 9:1577-86; PMID:23584251; http://dx.doi.
org/10.4161/hv.24615

Volume 10 Issue 2

©2014 Landes Bioscience. Do not distribute.

18. Ge X, Tan V, Bollyky PL, Standifer NE, James EA,
Kwok WW. Assessment of seasonal influenza A
virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol
2010; 84:3312-9; PMID:20071564; http://dx.doi.
org/10.1128/JVI.02226-09
19. Ellebedy AH, Fabrizio TP, Kayali G, Oguin TH
3rd, Brown SA, Rehg J, Thomas PG, Webby RJ.
Contemporary seasonal influenza A (H1N1) virus
infection primes for a more robust response to split
inactivated pandemic influenza A (H1N1) Virus
vaccination in ferrets. Clin Vaccine Immunol 2010;
17:1998-2006; PMID:20962210; http://dx.doi.
org/10.1128/CVI.00247-10
20. Novartis announces positive clinical trial results for
novel H7N9 vaccine [Internet]. Basel, Switzerland:
Novartis, Inc; 2013 Nov 13 [cited 2014 Jan 28].
Available from: http://www.novartis.com/newsroom/media-releases/en/2013/1743124.shtml
21. Fries LF, Smith GE, Glenn GM. A recombinant
viruslike particle influenza A (H7N9) vaccine. N
Engl J Med 2013; 369:2564-6; PMID:24224560;
http://dx.doi.org/10.1056/NEJMc1313186
22. Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H,
Gao X, Teng Z, Li J, Hu J, et al. Human Antibody
Responses to Avian Influenza A(H7N9) Virus,
2013. Emerg Infect Dis 2014; 20:192-200;
PMID:24447423;
http://dx.doi.org/10.3201/
eid2002.131094
23. Griffin MR, Monto AS, Belongia EA, Treanor JJ,
Chen Q, Chen J, Talbot HK, Ohmit SE, Coleman
LA, Lofthus G, et al.; U.S. Flu-VE Network.
Effectiveness of non-adjuvanted pandemic influenza
A vaccines for preventing pandemic influenza acute
respiratory illness visits in 4 U.S. communities. PLoS
One 2011; 6:e23085; PMID:21857999; http://
dx.doi.org/10.1371/journal.pone.0023085
24. Goodwin K, Viboud C, Simonsen L. Antibody
response to influenza vaccination in the elderly:
a quantitative review. Vaccine 2006; 24:1159-69;
PMID:16213065;
http://dx.doi.org/10.1016/j.
vaccine.2005.08.105
25. Grohskopf LA, Shay DK, Shimabukuro TT, Sokolow
LZ, Keitel WA. Bresee, JS, Cox, NJ. Prevention
and Control of Seasonal Influenza with Vaccines:
Recommendations of the Advisory Committee on
Immunization Practices – United States, 2013-2014
[Internet]. Atlanta, Georgia: Centers for Disease
Control) MMWR; 20 Sep 2013 [cited 01 Feb 2014].
Available from: http://www.cdc.gov/mmwr/preview/
mmwrhtml/rr6207a1.htm
26. de Wit E, Munster VJ, Spronken MI, Bestebroer TM,
Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus
AD, Fouchier RA. Protection of mice against lethal
infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 2005; 79:12401-7;
PMID:16160167;
http://dx.doi.org/10.1128/
JVI.79.19.12401-12407.2005
27. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major
D, Kuhne M, Höschler K, Saville M, Vogel FR,
Barclay W, et al. A phase I clinical trial of a PER.
C6 cell grown influenza H7 virus vaccine. Vaccine
2009; 27:1889-97; PMID:19368768; http://dx.doi.
org/10.1016/j.vaccine.2009.01.116
28. CDC statement on narcolepsy following Pandemrix
influenza vaccination in Europe [Internet]. Atlanta,
Georgia: Centers for Disease Control and Prevention;
2013 Feb 26 [cited 2014 Jan 29] Available from:
http://cdc.gov/vaccinesafety/Concerns/h1n1_narcolepsy_pandemrix.html
29. Eurosurveillance editorial team. Swedish Medical
Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro Surveill
2011; 16:19904; PMID:21745441

